4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Income from Continuing Operations of 94911000.0 for Q1 2026, down 91.98% year-over-year from 1182834617.85 in Q1 2025, and down 626.73% quarter-over-quarter from 18019000.0 in Q4 2025.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Income from Continuing Operations for 7 consecutive years, with 94911000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 91.98% year-over-year to 94911000.0; the TTM figure through Mar 2026 stood at 252655000.0 (down 13.1% YoY), while the FY2025 annual figure was 298627000.0, down 3.38% from the prior year.
- Income from Continuing Operations slipped to 94911000.0 in Q1 2026 per FDMT's latest filing, from 18019000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 18019000.0 in Q4 2025 and bottomed at 94911000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 48399470.59 across 5 years, with a median of 47319000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 217.09% — and 2025, when it jumped 135.65%.
- 4D Molecular Therapeutics' Income from Continuing Operations stood at 30282000.0 in 2022, then dropped by 9.21% to 33072000.0 in 2023, then tumbled by 52.85% to 50550000.0 in 2024, then surged by 135.65% to 18019000.0 in 2025, then plunged by 626.73% to 94911000.0 in 2026.
- Business Quant data shows FDMT's Income from Continuing Operations at 94911000.0 in Q1 2026, 18019000.0 in Q4 2025, and 85876000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -72.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -72.77 Mn |
| Mar 31, 2026 | -74.53 Mn |
| Dec 31, 2025 | 19.42 Mn |
| Sep 30, 2025 | -56.86 Mn |
| Jun 30, 2025 | -54.60 Mn |
| Mar 31, 2025 | -53.52 Mn |
| Dec 31, 2024 | -49.65 Mn |
| Sep 30, 2024 | -43.84 Mn |
| Jun 30, 2024 | -42.64 Mn |
| Mar 31, 2024 | -38.26 Mn |
| Dec 31, 2023 | -32.27 Mn |
| Sep 30, 2023 | -10.10 Mn |
| Jun 30, 2023 | -31.52 Mn |
| Mar 31, 2023 | -29.18 Mn |
| Dec 31, 2022 | -27.38 Mn |
| Sep 30, 2022 | -25.70 Mn |
| Jun 30, 2022 | -28.83 Mn |
| Mar 31, 2022 | -27.39 Mn |
| Dec 31, 2021 | -25.08 Mn |
| Sep 30, 2021 | -22.23 Mn |